GU Cancers 2025 | CheckMate 9ER: long term findings of nivolumab with cabozantinib in aRCC
Tian Zhang
• 15 Feb 2025
Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, shares final long-term results from the Phase III CheckMate 9ER trial (NCT03141177) of nivolumab plus cabozantinib veusus sunitinib in previously untreated advanced renal cell carcinoma (aRCC). Nivolumab and cabozantinib demonstrated improved progression-free and overall survival, as well as higher response rates across all risk groups. No new safety signals emerged, and treatment-related adverse events remained consistent with previous data. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
